Skip to Content

Pumarix

Active Substance: pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) 
Common Name: pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
ATC Code: J07BB02
Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.  
Active Substance: pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) 
Status: Withdrawn
Authorisation Date: 2011-03-04
Therapeutic Area: Influenza, Human Immunization Disease Outbreaks
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

Prophylaxis of influenza in an officially declared pandemic situation.

Pandemic-influenza vaccine should be used in accordance with official guidance.

The marketing authorisation for Pumarix has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide